Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

GFAP alternative splicing regulates glioma cell-ECM interaction in a DUSP4-dependent manner.

van Bodegraven EJ, van Asperen JV, Sluijs JA, van Deursen CBJ, van Strien ME, Stassen OMJA, Robe PAJ, Hol EM.

FASEB J. 2019 Aug 31:fj201900916R. doi: 10.1096/fj.201900916R. [Epub ahead of print]

PMID:
31480854
2.

Importance of GFAP isoform-specific analyses in astrocytoma.

van Bodegraven EJ, van Asperen JV, Robe PAJ, Hol EM.

Glia. 2019 Aug;67(8):1417-1433. doi: 10.1002/glia.23594. Epub 2019 Jan 22. Review.

3.

Systematic Three-Dimensional Coculture Rapidly Recapitulates Interactions between Human Neurons and Astrocytes.

Krencik R, Seo K, van Asperen JV, Basu N, Cvetkovic C, Barlas S, Chen R, Ludwig C, Wang C, Ward ME, Gan L, Horner PJ, Rowitch DH, Ullian EM.

Stem Cell Reports. 2017 Dec 12;9(6):1745-1753. doi: 10.1016/j.stemcr.2017.10.026. Epub 2017 Nov 30.

4.

Cortical Morphogenesis during Embryonic Development Is Regulated by miR-34c and miR-204.

Venø MT, Venø ST, Rehberg K, van Asperen JV, Clausen BH, Holm IE, Pasterkamp RJ, Finsen B, Kjems J.

Front Mol Neurosci. 2017 Feb 9;10:31. doi: 10.3389/fnmol.2017.00031. eCollection 2017.

5.

Human astrocytes are distinct contributors to the complexity of synaptic function.

Krencik R, van Asperen JV, Ullian EM.

Brain Res Bull. 2017 Mar;129:66-73. doi: 10.1016/j.brainresbull.2016.08.012. Epub 2016 Aug 25. Review.

6.

Physiologically Based Absorption Modeling to Impact Biopharmaceutics and Formulation Strategies in Drug Development-Industry Case Studies.

Kesisoglou F, Chung J, van Asperen J, Heimbach T.

J Pharm Sci. 2016 Sep;105(9):2723-2734. doi: 10.1016/j.xphs.2015.11.034. Epub 2016 Jan 23.

PMID:
26886317
7.

Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease.

Koshibu K, van Asperen J, Gerets H, Garcia-Ladona J, Lorthioir O, Courade JP.

Pharmacology. 2015;96(5-6):240-7. doi: 10.1159/000439136. Epub 2015 Sep 18.

PMID:
26382237
8.

Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain.

Mingorance-Le Meur A, Ghisdal P, Mullier B, De Ron P, Downey P, Van Der Perren C, Declercq V, Cornelis S, Famelart M, Van Asperen J, Jnoff E, Courade JP.

Br J Pharmacol. 2013 Nov;170(5):1053-63. doi: 10.1111/bph.12343.

9.

Behavioural effects and kinetics in brain in response to inhalation of constant or fluctuating toluene concentrations in the rat.

Lammers JH, van Asperen J, de Groot D, Rijcken WR.

Environ Toxicol Pharmacol. 2005 May;19(3):625-34. doi: 10.1016/j.etap.2004.12.028.

PMID:
21783535
11.

The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.

van Asperen J, van Tellingen O, Beijnen JH.

Drug Metab Dispos. 2000 Mar;28(3):264-7.

PMID:
10681369
12.

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH.

Br J Cancer. 1999 Jan;79(1):108-13.

13.

Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

van Asperen J, van Tellingen O, Schinkel AH, Beijnen JH.

J Pharmacol Exp Ther. 1999 Apr;289(1):329-33.

PMID:
10087021
14.

The hypothalamus: cross-roads of endocrine and behavioural regulation in grooming and aggression.

Kruk MR, Westphal KG, Van Erp AM, van Asperen J, Cave BJ, Slater E, de Koning J, Haller J.

Neurosci Biobehav Rev. 1998;23(2):163-77. Review.

PMID:
9884110
15.

High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.

van Tellingen O, Kemper M, Tijssen F, van Asperen J, Nooijen WJ, Beijnen JH.

J Chromatogr B Biomed Sci Appl. 1998 Nov 20;719(1-2):251-7.

PMID:
9869389
16.

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH.

Clin Cancer Res. 1998 Oct;4(10):2293-7.

17.

Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.

van Asperen J, van Tellingen O, Beijnen JH.

J Chromatogr B Biomed Sci Appl. 1998 Aug 7;712(1-2):129-43.

PMID:
9698235
18.

The pharmacological role of P-glycoprotein in the intestinal epithelium.

Van Asperen J, Van Tellingen O, Beijnen JH.

Pharmacol Res. 1998 Jun;37(6):429-35. Review.

PMID:
9695116
19.

Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.

van Tellingen O, Nooijen WJ, Schaaf LJ, van der Valk M, van Asperen J, Henrar RE, Beijnen JH.

Cancer Res. 1998 Jun 1;58(11):2410-6.

20.

The functional role of P-glycoprotein in the blood-brain barrier.

van Asperen J, Mayer U, van Tellingen O, Beijnen JH.

J Pharm Sci. 1997 Aug;86(8):881-4. Review. No abstract available.

PMID:
9269863
21.

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O.

Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5.

22.

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH.

Br J Cancer. 1997;76(9):1181-3.

23.

Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P, Schinkel AH.

Br J Pharmacol. 1996 Nov;119(5):1038-44.

24.

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O.

J Natl Cancer Inst. 1996 Jul 17;88(14):994-9.

PMID:
8667431

Supplemental Content

Loading ...
Support Center